Benjamin Lockshin, MD, FAAD

Benjamin Lockshin, MD, noted long half-life biologics may allow patients to maintain remission with minimal injections.

Ben Lockshin, MD, FAAD, covered ways in which GLP-1 RAs can be utilized when treating psoriatic disease.

Panelists discuss how age restrictions for PDE4 inhibitors affect treatment decisions for pediatric patients with atopic dermatitis, addressing parental concerns and highlighting the benefits of a single treatment option like roflumilast for managing overlapping inflammatory dermatologic conditions; they also explore current guidelines for corticosteroid use, the potential impact of PDE4 inhibitors on these guidelines, and the future of topical PDE4 inhibitors in dermatology, including the integration of new agents into treatment paradigms and key considerations for patient education and decision-making.

Panelists discuss how age restrictions for PDE4 inhibitors affect treatment decisions for pediatric patients with atopic dermatitis, addressing parental concerns and highlighting the benefits of a single treatment option like roflumilast for managing overlapping inflammatory dermatologic conditions; they also explore current guidelines for corticosteroid use, the potential impact of PDE4 inhibitors on these guidelines, and the future of topical PDE4 inhibitors in dermatology, including the integration of new agents into treatment paradigms and key considerations for patient education and decision-making.

Panelists discuss common misconceptions about the mechanism of action of PDE4 inhibitors in clinical practice, emphasizing that not all PDE4 inhibitors are created equal and how these differences can significantly impact their efficacy and safety profiles.

Panelists discuss the current landscape of topical treatments for atopic dermatitis, focusing on the evolution of nonsteroidal options over the past decade, and explain the mechanism of action of PDE4 inhibitors in specifically targeting inflammatory pathways associated with the condition.

Panelists discuss how topical PDE4 inhibitors compare to traditional treatments like corticosteroids in terms of efficacy, safety, and long-term disease control, while also examining the unique formulations of roflumilast and crisaborole and their implications for skin penetration and patient experience; they highlight practical considerations for application, the management of adverse effects such as stinging and burning, and the distinct advantages of PDE4 inhibitors in addressing specific gaps in atopic dermatitis management for various patient subgroups.

Panelists discuss the current landscape of topical treatments for atopic dermatitis, focusing on the evolution of nonsteroidal options over the past decade, and explain the mechanism of action of PDE4 inhibitors in specifically targeting inflammatory pathways associated with the condition.

Panelists discuss how to optimize plaque psoriasis treatment in a 32-year-old man, with a specific focus on addressing genital plaques to enhance patient comfort and improve overall treatment outcomes.

Panelists discuss how to develop tailored treatment approaches for a 34-year-old African American woman with plaque psoriasis, focusing on exploring nonsystemic options that consider her specific demographic and clinical profile.

Panelists discuss how to effectively manage plaque psoriasis in a 55-year-old man by evaluating and potentially combining topical treatments with systemic therapies for optimal disease control.

Lockshin shared his approach to continuing biologic therapies into pregnancy with informed timing adjustments.

Ben Lockshin, MD, FAAD, delves into the new generation of oral psoriasis therapies to enhance patient quality of life.

Benjamin Lockshin, MD, FAAD, summarizes the panel's best practices for improving patient education on the risks and benefits of vitiligo treatment. He underscores the importance of establishing and managing expectations for treatment response.

An expert in dermatology discusses the case of an active 71-year-old female who spends considerable time outdoors. The expert summarizes the panel's recommendations for counseling the patient on the benefits of treatment compliance and the use of sun-sparing products to enhance her quality of life and treatment response.

Benjamin Lockshin, MD, FAAD, summarizes key points from a panel discussion on the utilization of topical treatments in vitiligo. The first case revolves a 31-year-old woman with distressing depigmentation and highlights the panel's treatment approach to the management of this condition in difficult to treat areas.

Experts in dermatology share final thoughts on the treatment of plaque psoriasis and the ever-changing treatment landscape.

Benjamin Lockshin, MD, FAAD, highlights diversity in clinical trials as an unmet need in approaching the treatment of plaque psoriasis.

Expert dermatologists discuss the treatment guidelines for plaque psoriasis, and how the decision about treatment is ultimately in the hands of the clinician.

Nicholas Brownstone, MD, and James Q. Del Rosso, DO, comment on the psychological impact of plaque psoriasis on a patient’s quality of life.

Experts in dermatology review a patient case of a 48-year-old man with plaque psoriasis who is having trouble with topical therapy.

Dermatology experts discuss a patient case concerning a 60-year-old woman with chronic intertriginous psoriasis who is taking a biologic drug for inflammatory bowel disease.

Dawn L. Sammons, DO, FAOCD, FAAD, and Benjamin Lockshin, MD, FAAD, review a case of a female patient with a family history of plaque psoriasis.

Experts discuss the unique mechanism of action of tapinarof and its use in the treatment of plaque psoriasis.

James Q. Del Rosso, DO, and Dawn L. Sammons, DO, FAOCD, FAAD, review the efficacy of a new topical agent in the treatment of plaque psoriasis, tapinarof, highlighting the remittive data.

Experts in dermatology discuss newer topical treatments, such as tapinarof, in the management of plaque psoriasis.

Nicholas Brownstone, MD, comments on how newer treatments in plaque psoriasis can impact residency training.

Dawn L. Sammons, DO, FAOCD, FAAD, shares her approach to using topical vs systemic therapy in plaque psoriasis, focusing on patient preference as the driving factor for treatment selection.

Brad Glick, DO, FAOCD, highlights topical therapy as a targeted treatment of plaque psoriasis.

Benjamin Lockshin, MD, FAAD, comments on how the evolution of the pathophysiology of plaque psoriasis has led to more targeted therapies to treat the disease.